¶ VEGF and Angiogenesis Therapy
VEGF (Vascular Endothelial Growth Factor) and angiogenesis-based therapies represent a novel approach to treating neurodegenerative diseases by promoting blood vessel formation, improving cerebral blood flow, and enhancing neurovascular coupling. This approach addresses the vascular component of neurodegeneration in conditions like Alzheimer's disease and Parkinson's disease.
VEGF is a key regulator of angiogenesis and blood-brain barrier (BBB) function:
- VEGF-A: Primary isoform mediating angiogenesis and vascular permeability
- VEGF-B: Regulates vascular maintenance and energy metabolism
- VEGF-C/D: Lymphangiogenesis and lymphatic vessel development
- Angiogenesis: Formation of new blood vessels in the brain
- Blood-brain barrier modulation: Improved drug delivery potential
- Neuroprotection: Direct effects on neuronal survival through VEGF receptor signaling
- Cerebral blood flow enhancement: Improved perfusion of brain tissue
- PI3K/Akt pathway: Mediates VEGF-induced endothelial cell survival
- MAPK/ERK pathway: Controls endothelial cell proliferation
- Notch signaling: Regulates vessel maturation and patterning
- APP/PS1 mice: VEGF gene therapy improved cerebral blood flow and reduced amyloid burden
- 3xTg-AD mice: VEGF overexpression enhanced neurogenesis and cognitive function
- In vitro: VEGF protected against amyloid-beta-induced neuronal toxicity
- 6-OHDA lesioned rats: VEGF gene therapy promoted dopaminergic neuron survival
- MPTP mice: VEGF protected against dopaminergic neurodegeneration
- α-synuclein models: Angiogenic factors reduced pathology and improved motor function
¶ Stroke and Vascular Dementia
- Ischemic stroke models: VEGF promoted angiogenesis and functional recovery
- Chronic hypoperfusion models: VEGF improved cerebral blood flow and cognitive outcomes
| Compound |
Condition |
Phase |
Trial ID |
| AAV-VEGF |
Alzheimer's Disease |
Phase 1 |
NCT04762442 |
| Cilostazol |
Vascular Cognitive Impairment |
Phase 2 |
NCT03865394 |
| BMP9 |
Cerebral Amyloid Angiopathy |
Phase 1 |
NCT05532152 |
- NCT01098366: VEGF gene therapy for AD - completed 2014, showed safety but limited cognitive benefit
- NCT02600156: VEGF mimetic for PD - completed 2020, results published
- NCT02940574: Cilostazol for VCI - completed 2022, showed improvement in executive function
- Headache
- Dizziness
- Peripheral edema
- Hypertension
- Injection site reactions (for direct delivery)
¶ Risks and Concerns
- Angiogenesis in tumors: Potential to promote tumor growth if VEGF therapy reaches systemic circulation
- Vascular leakage: Increased blood-brain barrier permeability
- Pro-inflammatory effects: Potential for enhanced neuroinflammation
- Active malignancy
- Uncontrolled hypertension
- Recent stroke (acute phase)
- Severe cardiovascular disease
- AAV-VEGF: Adeno-associated virus-mediated VEGF expression
- Naked DNA VEGF plasmids: Non-viral gene delivery
- Cell-based therapy: VEGF-secreting stem cells
- Cilostazol: PDE3 inhibitor with anti-platelet and angiogenic properties
- Fingolimod: Sphingosine-1-phosphate modulator affecting vascular function
- Statins: Pleiotropic effects including angiogenesis
- Recombinant VEGF proteins: Direct protein delivery
- VEGF mimetics: Engineered peptides with VEGF-like activity
- Antibody-based approaches: VEGF neutralizing antibodies (typically for cancer)